Tris Pharma announced acceptance of a peer-reviewed publication exploring dual NOP-MOP receptor agonists as a promising new class of pain medications that may provide potent analgesia while substantially reducing the risks of abuse, addiction, and overdose associated with traditional opioids. The article, “The Therapeutic Potential of Dual-NMR (NOP/MOP) Agonism in Pain Management,” will be published in the journal Pain and Therapy.
Dual NOP-MOP agonists simultaneously activate two distinct opioid receptor systems. The NOP receptor, discovered in 1995, produces analgesia while minimizing many side effects associated with MOP-only activation found in drugs like morphine and oxycodone. By combining both receptors, dual-NMR drugs offer pain relief while mitigating physical dependence, tolerance, addiction, and respiratory depression.
Development and clinical promise
Tris Pharma is developing cebranopadol, a first-in-class investigational dual-NMR agonist studied in over 33 clinical trials involving more than 2,200 subjects. The drug has demonstrated positive clinical results across acute pain, chronic pain, and diabetic neuropathic pain with a favorable safety profile. The FDA granted Fast Track Designation to cebranopadol for chronic low back pain, and if approved, it could become the first dual-NMR therapy offering efficacy equivalent to selective MOP agonists with less risk of misuse or dependence.
Dr. Roberto Ciccocioppo, a co-author and Professor of Pharmacology at the University of Camerino, stated that dual-NMR agonists “represent an important new breakthrough in pain management.” The National Institute on Drug Abuse has awarded Tris a five-year grant of up to $16.6 million to study cebranopadol’s potential in treating opioid use disorder and substance use disorders.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110573160/Tris-Pharma-Announces-Acceptance-Of-New-Publication-Highlighting-Promise-Of-Dual-NOP-MOP-Dual-NMR-Agonists-For-The-Treatment-Of-Moderate-To-Severe-Pain